Abstract
Background: The high prevalence of obesity and non-alcoholic fatty acid disease has become an important public health problem. Daesiho-tang (DST) is an herbal medicine widely used to treat obesity, metabolic syndrome and liver diseases. This pilot study will assess the feasibility of using DST in obese patients with a non-alcoholic fatty liver disease (NAFLD) prior to undertaking a full-scale clinical trial.
Methods: This is a study protocol for a randomised, double-blind, parallel-group, stratified, placebo-controlled pilot trial. We will recruit a total of 60 participants with body mass index ≥ 25 kg/m2 and will have NAFLD. They will take either DST or placebo (3 g, three times daily) for 12 weeks with a 4-week follow-up period. The effects of DST will be evaluated by the mean change in body weight as the primary measurement and other secondary parameters (body composition, anthropometric measurements, blood tests, hepatic fat quantification through transient elastography and a physical symptoms questionnaire). Faecal samples will be collected before and after the intervention for a gut microbial analysis.
Discussion: This study will explore the effect of DST on weight loss and obesity-related markers, along with NAFLD-related clinical parameters in obese patients with NAFLD to conduct further large-scale trials. Furthermore, it will provide insight into the DST pharmacological mechanism of action through a gut microbiome analysis
Trial registration: Korean Clinical Trial Registry, KCT0003554. Registered on 25 February 2019, https://cris.nih.go.kr/cris/search/search_result_st01_en.jsp?seq=13379
Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis
